DAPT – Medxy AI

DOACs After Left Atrial Appendage Closure: Enhancing Safety Without Compromising Efficacy in the ANDES Trial

By MedXY 01/18/2026

The ANDES randomized trial demonstrates that 60-day DOAC therapy post-LAAC significantly reduces bleeding events compared to DAPT, while maintaining comparable rates of device-related thrombosis, suggesting a superior safety profile for short-term anticoagulation.

Cardiology Internal Medicine news

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

By MedXY 01/17/2026

The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering ischemic risks without increasing bleeding.

Internal Medicine Neurology news

The 42-Hour Window: Why Delaying Dual Antiplatelet Therapy Compromises Outcomes in Minor Stroke and High-Risk TIA

By MedXY 01/07/2026

A large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 hours.